GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

Inclusion Criteria: * biopsy proved CD20+ DLBCL; * previously received at least one systemic treatment (including chemotherapy) without remission or relapse after remission; * at least one evaluable lesion； * ECOG PS 0-1; * 18-65 years; * proper functioning of the major organs. Exclusion Criteria: * involvement of central nervous system; * with other malignancy; * patients receiving or received drug of other clinical trial within 30 days； * previously received doxorubicin liposome or have used other anthracycline drug with accumulated restricted doses (adriamycin 450mg/m2, epirubicin 935mg/m2, acrarubicin 900mg/m2)； * patients who received treatment for hematologic toxicity caused by previous chemotherapy within 7 days before enrollment; * grade 2 or more peripheral neuropathy.